1. OUTCOMES OF PATIENTS ≥ 65 YEARS OF AGE IN ZUMA‐1, A PIVOTAL PHASE 1/2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN REFRACTORY LARGE B CELL LYMPHOMA. (12th June 2019) Authors: Neelapu, S.S.; Jacobson, C.A.; Oluwole, O.O.; Munoz, J.; Deol, A.; Miklos, D.B.; Bartlett, N.L.; Braunschweig, I.; Jiang, Y.; Kim, J.J.; Zheng, L.; Rossi, J.M.; Locke, F.L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL). (June 2017) Authors: Neelapu, S.S.; Rossi, J.M.; Locke, F.L.; Xue, A.; Better, M.; Zhang, X.; Ghobadi, A.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.M.; Navale, L.; Go, W.Y.; Wiezorek, J.; Bot, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗